Fréderique de Graaf
LUMC
Dr. Fréderique de Graaf obtained her doctoral degree on avian paramyxoviruses and their application in oncolytic viro-immunotherapy at the Viroscience department of the Erasmus Medical Center, Rotterdam. During these doctoral studies, she developed new viral vectors to improve environmental safety and treatment efficacy of oncolytic viruses. From 2020 until 2023, she worked as a postdoc/scientist at Immunetune on synthetic linear DNA as a novel platform for personalized neoantigen vaccines. In collaboration with Leiden University Medical Center (LUMC), she evaluated the anti-tumor efficacy of personalized DNA vaccines with or without checkpoint inhibitor therapy in several models, while putting this research into perspective of the development of a clinical product. In 2023, she started working at the LUMC to contribute further to the development of immune modulatory anti-cancer therapies.
LinkedIn: /frederique-de-graaf/